Nexus DX specializes in advanced in vitro diagnostic (IVD) technologies, particularly through its IB10 platform. This platform includes a range of rapid point-of-care (POC) immunoassays designed for the quantitative determination of various biomarkers in human blood and plasma. Key products include tests for cardiac troponin (Troponin-99), N-terminal pro-brain natriuretic peptide (NT-proBNP), D-Dimer, thyroid-stimulating hormone (TSH), and procalcitonin (PCT), among others. These tests utilize different anticoagulants such as lithium heparin and EDTA, enabling healthcare providers to obtain critical diagnostic information quickly and efficiently.

The IB10 technology is particularly notable for its application in personalized medicine, as evidenced by its involvement in biomarker-guided trials, such as those related to COVID-19. The platform's ability to assess acute kidney injury in children through the proenkephalin (penKid) test highlights its role in addressing diagnostic challenges in various medical conditions. Overall, Nexus DX's innovative approach to IVD technology aims to enhance patient care by providing timely and accurate diagnostic results.

United States

Nexus Dx is a global provider of Near Patient Testing systems and advanced diagnostic solutions.  The company is improving patient care by providing the medical community with rapid and reliable information at the point of care (POC), delivering patient information when and where it is needed most.

Company Highlights:

Primary focus on expansion of assay systems in the Near Patient Testing industry
Multi-product revenue generating business
Proprietary technologies and content
Highly experienced management team

Nexus Dx Inc.

Nexus DX

Company Details